Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 65
Filter
1.
Rev. chil. endocrinol. diabetes ; 17(1): 13-15, 2024.
Article in Spanish | LILACS | ID: biblio-1525710

ABSTRACT

Se comunican 2 personas transfemeninas (transgénero de varón a mujer) que consultaron al endocrinólogo a los 20 años para terapia hormonal de afirmación de género. Durante los primeros 18 meses fueron tratadas con esquema múltiple clásico con análogos del GnRH o Medroxiprogesterona, espironolactona o flutamida y gel de estrógeno; no se logró descender la testosterona plasmática constatándose muy escasa desmasculinización. Cumplido estrictamente el tratamiento se comprobó una persistente frenación de gonadotrofinas en ambos casos. Este hecho sugirió una fuente androgénica patológica testicular o suprarrenal. Esta última se descartó por haber acusado una pubertad normal y por ausencia de masas suprarrenales. Una de las transfemeninas presentó un tumor testicular cuya histopatología demostró un seminoma. Se analiza el impacto de esta terapia hormonal feminizante en el testículo, más aún con el antecedente de criptorquidea. La terapia hormonal permitió desenmascarar el tumor testicular y realizar su tratamiento precoz. PET/ CT de control poscirugía (-). En ambas transfemeninas solo la orquiectomía bilateral logró bajar la testosterona plasmática al nivel de lo señalado como feminización.


This study explores the case of two transfeminine (male-to-female transgender) individuals who initiated gender-affirming hormone therapy in adulthood, whose plasma testosterone levels remained unresponsive during the first 18 months of gender affirming hormone therapy, including analogues of GnRH or Medroxyprogesterone to curb gonadotropins, spironolactone or flutamide as antiandrogens, as well as estrogen gel. Minimal demasculinization was observed. After strictly following treatment, a complete and persistent gonadotropin suppression was confirmed. This fact suggested a pathological androgenic testicular or adrenal source. An adrenal origin was discarded due to the patient's normal puberty and absence of adrenal masses. There was no self-administration of exogenous testosterone. In both transfeminine cases, bilateral orchiectomy was the sole intervention that effectively reduced plasma testosterone to feminizing levels (under 50 ng/dl). One of the cases presented a testicular tumor, the histology of which revealed a pure seminoma. The impact of this hormone therapy on the testicle is analyzed. In both, testosterone reached levels of feminization only with orchiectomy.


Subject(s)
Humans , Male , Female , Young Adult , Testicular Neoplasms/diagnosis , Testosterone/analysis , Transsexualism/drug therapy , Hormones/therapeutic use , Spironolactone , Gonadotropin-Releasing Hormone , Seminoma , Feminization , Transgender Persons , Gender Identity , Androgen Antagonists , Medroxyprogesterone
2.
Rev. cuba. endocrinol ; 31(3): e203, sept.-dic. 2020. tab
Article in Spanish | LILACS, CUMED | ID: biblio-1156393

ABSTRACT

Introducción: Las bases fisiopatológicas del Síndrome de ovario poliquístico pueden predisponer a mayor riesgo de autoinmunidad a las mujeres que tienen esta condición y existen evidencias, aunque escasas, de mayor prevalencia de autoinmunidad tiroidea en ellas. Objetivos: Determinar la frecuencia de marcadores serológicos de autoinmunidad tiroidea en mujeres con Síndrome de ovario poliquístico e identificar si existe asociación entre la presencia de ellos y las concentraciones de progesterona y testosterona. Métodos: Se realizó un estudio en 50 mujeres con Síndrome de ovario poliquístico y 50 sin el síndrome. Se realizaron determinaciones de autoanticuerpos tiroideos (anti tiroglobulina (Anti-Tg) y anti peroxidasa (anti-TPO) a las mujeres de ambos grupos de estudio. Se realizaron determinaciones de hormonas (testosterona y progesterona) solo al grupo de estudio de mujeres con SOP. Se crearon categorías por anticuerpos: Positivo si los títulos fueron superior al rango de referencia y negativo dentro del rango. Se consideró respuesta autoinmune positiva, cuando al menos uno de los anticuerpos se encontró elevado. Para la asociación entre la presencia de autoinmunidad y las variables independientes se hicieron análisis bivariados mediante comparación de medias y test no paramétricos. Se consideró un nivel de significancia de α = 0,05. Resultados: En las mujeres con Síndrome de ovario poliquístico, 62 por ciento mostraron anticuerpos positivos y 14 por ciento en las sin el síndrome. En las mujeres sin síndrome, de las 7 mujeres con marcadores de autoinmunidad positivos, en 6 (85,7 por ciento) el anti-Tg fue el que dio positivo. No hubo diferencias significativas en cuanto a la asociación con los niveles de testosterona y progesterona. Conclusiones: Las mujeres con Síndrome de ovario poliquístico tienen mayor frecuencia de desarrollar respuesta autoinmune tiroidea, independiente de los niveles de progesterona y testosterona(AU)


Introduction: The physio-pathological bases of polycystic ovary syndrome may predispose women with this condition to a higher risk of autoimmunity and there is evidence, albeit scarce, of higher prevalence of thyroid autoimmunity in them. Objectives: Determine the frequency of serological markers of thyroid autoimmunity in women with polycystic ovary syndrome and identify whether there is an association between the presence of them and progesterone and testosterone concentrations. Methods: A study was conducted in 50 women with polycystic ovary syndrome and 50 without the syndrome. Determinations of thyroid autoantiantibodies (anti-thyroglobulin (Anti-Tg) and anti-peroxidase (anti-TPO) were made to women in both study groups. Hormone determinations (testosterone and progesterone) were made only to the study group of women with PCOS. Categories were created by antibodies: Positive if the titles were greater than the reference range, and negative if within the range. It was considered a positive autoimmune response when at least one of the antibodies was found increased. For the association between the presence of autoimmunity and independent variables, bivariate analyses were performed by means comparison and non-parametric tests. It was considered a significance level of α =0.05. Results: In women with polycystic ovary syndrome, 62 percent showed positive antibodies and 14 percent in those without the syndrome. In women without the syndrome, of the 7 women with positive autoimmune markers, in 6 (85.7 percent) the anti-Tg was the one that tested positive. There were no significant differences in the association with testosterone and progesterone levels. Conclusions: Women with polycystic ovary syndrome are more often able to develop thyroid autoimmune response, independently from the progesterone and testosterone levels(AU)


Subject(s)
Humans , Polycystic Ovary Syndrome/epidemiology , Thyroid Gland/physiopathology , Autoimmunity/physiology , Hormones/analysis , Antibodies , Testosterone/analysis , Thyroglobulin/administration & dosage , Case-Control Studies
3.
Rev. Hosp. Ital. B. Aires (2004) ; 40(1): 34-38, mar. 2020. tab
Article in Spanish | LILACS | ID: biblio-1102292

ABSTRACT

Las mujeres han sido tratadas por décadas con testosterona intentando aliviar una gran variedad de síntomas con riesgos y beneficios inciertos. En la mayoría de los países, la testosterona se prescribe "off-label", de modo que las mujeres están utilizando compuestos y dosis ideadas para tratamientos en hombres. En este sentido, varias sociedades médicas de distintos continentes adoptaron recientemente por consenso una toma de posición sobre los beneficios y potenciales riesgos de la terapia con testosterona en la mujer, explorar las áreas de incertidumbre e identificar prácticas de prescripción con potencial de causar daño. Las recomendaciones con respecto a los beneficios y riesgos de la terapia con testosterona se basan en los resultados de ensayos clínicos controlados con placebo de al menos 12 semanas de duración. A continuación se comentan las recomendaciones. (AU)


There are currently no clear established indications for testosterone replacement therapy for women. Nonetheless, clinicians have been treating women with testosterone to alleviate a variety of symptoms for decades with uncertainty regarding its benefits and risks. In most countries, testosterone therapy is prescribed off-label, which means that women are using testosterone formulations or compounds approved for men with a modified dose for women. Due to these issues, there was a need for a global Consensus Position Statement on testosterone therapy for women based on the available evidence from placebo randomized controlled trials (RCTs). This Position Statement was developed to inform health care professionals about the benefits and potential risks of testosterone therapy intended for women. The aim of the Consensus was to provide clear guidance as to which women might benefit from testosterone therapy; to identify symptoms, signs, and certain conditions for which the evidence does not support the prescription of testosterone; to explore areas of uncertainty, and to identify any prescribing practices that have the potential to cause harm. (AU)


Subject(s)
Humans , Female , Aged , Testosterone/therapeutic use , Postmenopause/drug effects , Appetite Depressants/adverse effects , Phenytoin/adverse effects , Placebos/administration & dosage , Psychotropic Drugs/adverse effects , Tamoxifen/adverse effects , Testosterone/administration & dosage , Testosterone/analysis , Testosterone/adverse effects , Testosterone/pharmacology , Cardiovascular Agents/adverse effects , Indomethacin/adverse effects , Gonadotropin-Releasing Hormone/adverse effects , Postmenopause/physiology , Controlled Clinical Trials as Topic , Cholinergic Antagonists/adverse effects , Contraceptives, Oral/adverse effects , Sexual Dysfunctions, Psychological/etiology , Sexual Dysfunctions, Psychological/therapy , Danazol/adverse effects , Consensus , Aromatase Inhibitors/adverse effects , Off-Label Use , Factor Xa Inhibitors/adverse effects , Amphetamines/adverse effects , Histamine Antagonists/adverse effects , Androgen Antagonists/adverse effects , Androgens/physiology , Ketoconazole/adverse effects , Narcotics/adverse effects
4.
Rev. bras. ciênc. vet ; 26(3): 87-92, jul./set. 2019. il.
Article in Portuguese | LILACS, VETINDEX | ID: biblio-1390975

ABSTRACT

Objetivou-se avaliar características quali - quantitativas da carcaça em machos Nelore, submetidos ao bloqueio dos ductos incisivos no período pré puberal. Além disso, objetivou-se avaliar as concentrações séricas de testosterona e do hormônio do crescimento semelhante a insulina do tipo I (IGF-I), e a arquitetura histológica do órgão vomeronasal (OVN). Trinta e quatro machos, no período pré puberal, foram divididos em três grupos experimentais: inteiros ­ animais controle sem qualquer procedimento (n = 11); bloqueados - animais com os ductos incisivos bilateralmente obstruídos (n = 10); castrados - animais com orquiepididectomia bilateral (n = 13). O OVN foi obtido no abate, ao final do experimento, para avaliação histomorfométrica. As coletas de sangue foram realizadas a cada três meses, em dois turnos (manhã e tarde), totalizando cinco avaliações. Observaram-se maiores (P<0,05) pesos corporais finais (inteiros = 494,1 ± 28,71; bloqueados = 500,6 ± 23,6 e castrados = 468,3 ± 21,8 Kg) nos inteiros e bloqueados. O acabamento da carcaça foi maior nos castrados (P<0,05) em relação aos inteiros e bloqueados, enquanto o rendimento de carcaça não apresentou diferenças entre os três tratamentos (P>0,05). Registrou-se redução da altura do epitélio neuro sensitivo do OVN nos bloqueados e castrados (P<0,05). Foi registrada menor concentração de testosterona nos bloqueados nas coletas quatro e cinco à tarde (P<0,05). Conclui-se que a obstrução dos ductos incisivos reduziu os estímulos sensoriais para o OVN, que por sua vez, promoveu alteração na concentração sérica de testosterona, sem alterar o ganho de peso dos animais, porém, não promoveu melhoria na qualidade da carcaça nas condições deste estudo.


A total of 34 prepuberal Nellore males were divided into three groups: control ­ animals without any procedure (n = 11); blocked - with bilaterally incisors ducts obstructed (n = 10); castrated - with bilateral orchiectomy (n = 13). This study aimed to evaluate the effect of blocking the vomeronasal organ (VNO) in qualitative and quantitative characteristics of the carcass. Also, this study aimed to evaluate testosterone and insulin-like growth factor (IGF-I) serum concentration, and the histological architecture of the OVN. Blood samples were taken every three months during two daily collections (morning and afternoon), totalizing five evaluations. It was observed higher (P<0.05) final body weight (control= 494.1 ± 28.71; blocked = 500.6 ± 23.6; castrated = 468.3 ± 21.8 kg) at the control and blocked groups. Carcass finishing was higher in castrated animals (P <0.05), while carcass yield did not differ between treatments (P> 0.05). It was observed a reduction (P<0.05) of the VNO sensory epithelium height in blocked and castrated groups compared with control group. It was registered lower (P<0.05) serum testosterone concentration in blocked group at the fourth and fifth blood collection (afternoon). It was concluded that the obstruction of the incisive ducts reduced the sensorial stimuli for the OVN, which, in turn, promoted a change in the serum concentration of testosterone, without altering the weight gain of the animals, but did not promote improvement in the quality of the carcass under the conditions of this study.


Subject(s)
Animals , Cattle , Olfactory Bulb/anatomy & histology , Testosterone/analysis , Insulin-Like Growth Factor I/analysis , Cattle/anatomy & histology , Weight Gain , Castration/veterinary , Vomeronasal Organ/anatomy & histology , Animal Culling
5.
Int. j. morphol ; 37(2): 515-521, June 2019. tab, graf
Article in English | LILACS | ID: biblio-1002253

ABSTRACT

SUMMARY: Reproductive dysfunction is a complication for many diseases and toxins. Its early diagnosis and treatment are immensely important. Here the morphological histoarchitecture changes in early testicular and cauda toxicity before and after treatment with angiotensin receptor blockers were evaluated. Low-grade testicular damage was induced using thioacetamide (TAA, 50 mg/kg/day) intraperitoneally for two weeks in rats. The rats were randomly divided into four groups (n = 8) treated daily orally for three weeks as follows: Normal control (distilled water), TAA (positive control), TAA+candesartan (0.2 mg/kg) and TAA+losartan (7.5 mg/kg). Serum testosterone and testicular malondialdehyde and glutathione were measured. The changes in histoarchitecture of testis and cauda epididymis were evaluated by hematoxylin and eosin for general structure, Masson's trichrome for collagen, periodic acid Schiff for basement membrane, and caspase-3 and proliferating cell nuclear antigen (PCNA) for immunohistochemical analysis. The TAA-rats showed decreases of serum testosterone and testicular glutathione, increases in testicular malondialdehyde, degenerative changes and apoptosis in germ cells, thickening of tubular basal lamina and increases in expression of caspase 3, and decreases in expression of PCNA. The ARBs (candesartan and losartan) significantly reversed these changes with non-significant differences in-between. Treatment with ARBs (candesartan and losartan) significantly reversed TAA-induced low-grade testicular and cauda toxicity in rats. This could be potentially useful for early treatment of male patients with occupational toxicant-induced reproductive dysfunction especially if they are using ARBs for other comorbidities.


RESUMEN: La disfunción reproductiva es una complicación por muchas enfermedades y toxinas. Su diagnóstico y tratamiento tempranos son inmensamente importantes. Aquí se evaluaron los cambios morfológicos en la histoarquitectura en la toxicidad precoz testicular y cauda antes y después del tratamiento con bloqueadores de receptores de angiotensina. Se indujo daño testicular de bajo grado usando tioacetamida (TAA, 50 mg / kg / día) por vía intraperitoneal durante dos semanas en ratas. Las ratas se dividieron aleatoriamente en cuatro grupos (n = 8) tratados diariamente por vía oral durante tres semanas de la siguiente manera: control normal (agua destilada), TAA (control positivo), TAA + candesartan (0,2 mg / kg) y TAA + losartán (7,5 mg / kg). Se midieron la testosterona sérica, el malondialdehído testicular y el glutatión. Los cambios en la histoarquitectura de los testículos y la epidermis de la cauda se evaluaron mediante Hematoxilina y Eosina para determinar la estructura general, con tricrómicro de Masson para el colágeno, ácido periódico de Schiff para la membrana basal y la caspasa-3 y el antígeno nuclear de células proliferantes (PCNA) para análisis inmunohistoquímico. Las ratas TAA mostraron disminución de la testosterona sérica y glutatión testicular, aumentos en el malondialdehído testicular, cambios degenerativos y apoptosis en células germinales, engrosamiento de la lámina basal tubular y aumentos en la expresión de la caspasa 3, y disminución en la expresión de PCNA. Los ARB (candesartán y losartán) revirtieron significativamente estos cambios con diferencias no significativas en el medio. El tratamiento con BRA (candesartán y losartán) revirtió significativamente la toxicidad testicular y cauda inducida por TAA en ratas. Esto podría ser potencialmente útil para el tratamiento temprano de pacientes con disfunción reproductiva inducida por tóxicos ocupacionales, especialmente si están usando BRA para otras comorbilidades.


Subject(s)
Animals , Male , Rats , Testis/drug effects , Thioacetamide/toxicity , Benzimidazoles/pharmacology , Losartan/pharmacology , Angiotensin II Type 1 Receptor Blockers/pharmacology , Testis/pathology , Testosterone/analysis , Tetrazoles/pharmacology , Immunohistochemistry , Rats, Sprague-Dawley , Proliferating Cell Nuclear Antigen/metabolism , Caspase 3/metabolism , Glutathione/analysis , Malondialdehyde/analysis
6.
Rev. chil. endocrinol. diabetes ; 12(1): 11-15, 2019. tab, ilus
Article in Spanish | LILACS | ID: biblio-982011

ABSTRACT

Clinical case: a girl of 7 ½ years who consulted for early pubarche without thelark, with a percentile size of 75 for a genetic target size in the 10th percentile, overweight with a 90th percentile BMI, and normal blood pressure. The biochemical study showed high levels of androgens: testosterone: 7.2 ng/dL, androstenedione of 5.1 ng / ml, 17OHP: 15 ng / dL with low normal DHEAS (0.26 ug/ml), Plasma Renin Activity normal low: 0.22 ng/mL/h. Initial imaging study showed a bone age of 10 years 6 months and normal abdominal and pelvic ultrasound. Molecular study showed no pathogenic variants in the CYP21A2 gene (21 Hydroxylase). With a probable diagnosis of non-classical congenital adrenal hyperplasia (HSRNC) and no known mutation, he started treatment with hydrocortisone (12 mg/m2). At 8.7 years, pubertal development begins and braking begins with LHRH analogues, which are administered for 18 months. Despite the treatment, signs of virilization and elevation of androgens (testosterone up to 130 ng/ml) are progressively accentuated, which do not diminish when trying different corticosteroid schemes. MRI of the abdomen and pelvis shows the normal adrenal glands and a solid nodular image of 2.1 x 1.6 cm in the right ovary (Figure 2), later demonstrated with pelvic ultrasound (Figure 2). Right laparoscopic oophorectomy was performed, whose biopsy demonstrated a Leydig cell tumor. One month after surgery, all androgenic levels were normalized, so the gradual suspension of corticosteroids began. Conclusion: Although HSRNC is the most frequent pathological cause of early pubarche, when it is associated with progressive clinical and biochemical hyperandrogenism despite adequate treatment and without pathogenic variants in the CYP21A2 gene, even with high levels of 17OHP, other causes should be considered, specifically, androgen producing tumors.


Caso clínico: niña de 7½ años que consulta por pubarquia precoz sin telarquia, con talla en percentil 75 para una talla objetivo genético en percentil 10, sobrepeso con IMC percentil 90 y presión arterial normal. El estudio bioquímico mostró niveles elevados de andrógenos: testosterona: 7,2 ng/dL, androstenediona de 5,1 ng/ml, 17OHP: 15 ng/dL con DHEAS normal baja (0,26 ug/ml), Actividad de Renina Plasmática normal baja: 0.22 ng/ mL/h. Estudio de imágenes inicial mostró una edad ósea de 10 años 6 meses y ecografía abdominal y pelviana normales. Estudio molecular no mostró variantes patogénicas en el gen CYP21A2 (21 Hidroxilasa). Con diagnosticó probable de hiperplasia suprarrenal congénita no clásica (HSRNC) y sin mutación conocida,inició el tratamiento con hidrocortisona (12 mg/m2). A los 8.7 años comienza desarrollo puberal y se inicia frenación con análogos de LHRH, los cuales se administran por 18 meses. A pesar del tratamiento se acentúan progresivamente los signos de virilización y hayelevación de los andrógenos (testosterona hasta 130 ng/ml), que no disminuyen intentando diferentes esquemas de corticoides. Se realiza RM de abdomen y pelvis que muestra las glándulas suprarrenales normales y una imagen nodular sólida de 2.1 x 1.6 cm en el ovario derecho (Figura 2), demostrada posteriormente con Ecografía pelviana (Figura 2). Se realiza ooforectomía derecha por vía laparoscópica, cuya biopsia demostró un tumor de células de Leydig. Un mes después de la cirugía, se normalizan todos los niveles androgénicos por lo que se inició la suspensión gradual de los corticoides. Conclusión: Aunque la HSRNC es la causa patológica más frecuente de la pubarquia precoz, cuando se asocia con un hiperandrogenismo clínico y bioquímico progresivo a pesar de un tratamiento adecuado y sin variantes patógenicas en el gen CYP21A2, incluso con niveles elevados de 17OHP, otras causas deben ser consideradas, específicamente tumores productores de andrógenos.


Subject(s)
Humans , Female , Child , Ovarian Neoplasms/complications , Ovarian Neoplasms/diagnosis , Puberty, Precocious/etiology , Leydig Cell Tumor/complications , Leydig Cell Tumor/diagnosis , Testosterone/analysis , Hyperandrogenism/etiology , Adrenal Hyperplasia, Congenital/diagnosis , 17-alpha-Hydroxyprogesterone/analysis , Hirsutism/etiology , Androgens/analysis , Androstenedione/analysis
7.
Rev. chil. endocrinol. diabetes ; 12(1): 23-25, 2019. ilus
Article in Spanish | LILACS | ID: biblio-982026

ABSTRACT

Ovarian steroid-producing tumors are infrequent entities and are potentially malignant. Testosterone is the hormone that rises more frequently and is associated mostly with signs of virilization. We present the clinical case of a 67-year-old postmenopausal woman who came to the clinic for alopecia, with high levels of testosterone and ovarian mass by ultrasound. Surgical treatment was indicated. The main diagnostic aspects are presented.


Los tumores productores de esteroides ováricos constituyen entidades infrecuentes y son potencialmente malignos. La testosterona es la hormona que se eleva con más frecuencia y se asocia en su mayoría a signos de virilización. Se presenta el caso clínico de una mujer postmenopáusica de 67 años que acude a consulta por alopecia, con niveles elevados de testosterona y masa ovárica por ecografía. Se indicó tratamiento quirúrgico. Se presentan los principales aspectos diagnósticos.


Subject(s)
Humans , Female , Aged , Ovarian Neoplasms/complications , Ovarian Neoplasms/diagnosis , Virilism/etiology , Postmenopause , Ovarian Neoplasms/surgery , Testosterone/analysis , Hyperandrogenism/etiology , Alopecia/etiology
8.
Rev. argent. endocrinol. metab ; Rev. argent. endocrinol. metab;55(3): 41-50, set. 2018.
Article in Spanish | LILACS | ID: biblio-1041743

ABSTRACT

RESUMEN El diagnóstico de hipogonadismo requiere de la presencia de síntomas y signos sugestivos de deficiencia de testosterona asociado a la confirmación por estudios de laboratorio de valores de testosterona por debajo del valor normal. Se ha descrito un aumento en la prescripción de la terapia androgénica en el hipoandrogenismo asociado con la edad, y existe preocupación sobre los potenciales efectos adversos en especial a nivel cardiovascular relacionados con la misma. Los mecanismos fisiopatológicos propuestos en relación a los posibles efectos adversos de la testosterona sobre el sistema cardiovascular incluyen: aumento de la expresión de receptor para tromboxano A2 (TXA2), aumento de la expresión vascular en células endoteliales de la molécula de adhesión vascular 1 (VCAM1), estimulación de la eritropoyesis con el desarrollo de policitemia, como también aumento de la incidencia de síndrome apnea del sueño. Pero por otra parte, existe evidencia de que el hipogonadismo no tratado se asocia a aumento de enfermedad cardiovascular y mortalidad. Se sugiere considerar la administración de TRH en pacientes con hipogonadismo sintomático, tomando en cuenta los riesgos y beneficios asociados a la misma y con precaución en su indicación en los pacientes más frágiles y con alto riesgo cardiovascular.


ABSTRACT The diagnosis of hypogonadism requires of the presence of symptoms and signs suggestive of testosterone deficiency associated with confirmation by laboratory studies of testosterone below the normal value. It has been described an increase in the prescription of androgenic therapy in late onset hypogonadism (associated with aging) and there is concern of its potential adverse effects, especially on cardiovascular events. The proposed physiopathological mechanisms, related to the adverse effects of testosterone on the cardiovascular system include: increased expression of thromboxane A2 receptors (TXA2), increased expression of vascular cell adhesion molecule-1 (VCAM1), stimulation of erythropoiesis with the development of polycythemia, as well as an increase in the incidence of sleep apnea syndrome. On the other hand, evidence exists on the association of not treated hypogonadism with an increase in cardiovascular disease and mortality. It is suggested to consider the use of testosterone therapy in patients with symptomatic hypogonadism, always taking into account the possible risks and benefits associated with its use and being careful on its indication in fragile patients with high cardiovascular risk.


Subject(s)
Cardiovascular Diseases/complications , Hormone Replacement Therapy/adverse effects , Hypogonadism/complications , Testosterone/analysis , Hypogonadism/mortality
9.
Int. j. morphol ; 36(2): 447-453, jun. 2018. tab, graf
Article in English | LILACS | ID: biblio-954135

ABSTRACT

Although Momordica charantia (MC) has preventive effects on tissue injuries, antioxidant capacity and protective effect of MC pulp and peel (MCP) on valproic acid (VPA)-testicular damage have never been reported. Fresh MCPs were aqueous extracted and determined for antioxidant capacity and momordicine I level by HPLC. Male rats were divided into 5 groups (control, VPA (500 mg/kgBW), MCP20/40/ or 80 mg/kgBW+VPA). In 30 experimental days, animals were pretreated with different doses of MCPs for 20 days before VPA injection for 10 consecutive days. Sperm concentration, testosterone hormone, and testicular histology of all groups were investigated. Expressions of testicular tyrosine phosphorylated and steroidogenic acute regulatory (StAR) proteins were examined by Western blot. Results showed that MCP contains TPC (39.24±0.65 ug/mg garlic acid), antioxidant capacities (FRAP=33.08±0.21 ug/ mg ascorbic acid equivalent, IC50 of DPPH=389.8±3.20 ug/ml), and momordicine I (404.9 mg/g MCP). Sperm concentration in MCP80+VPA group was increased as compared to VPA group. Testosterone level in MCP treated groups was significantly increased. MCP protected testicular damage and could prevent the decrease of StAR and a 50-kDa phosphorylated protein expression in VPAtreated testis. In conclusion, MCP has antioxidant activities and can prevent male reproductive toxicity in VPA-induced rats.


A pesar que la Momordica charantia (MC) tiene efectos preventivos sobre las lesiones en los tejidos, capacidad antioxidante y un efecto protector de la pulpa y la cáscara de MC (CMC) sobre el ácido valproico (AVP), aún no se ha informado efectos sobre el daño testicular. Las CMC frescas fueron extraídas de forma acuosa y se determinó la capacidad antioxidante y el nivel de Momordicina I por HPLC. Las ratas machos se dividieron en 5 grupos: control, AVP (500 mg/kg de peso corporal), CMC20 / 40 / u 80 mg/kg de peso corporal + AVP . En 30 días experimentales, los animales fueron pretratados con diferentes dosis de CMC durante 20 días antes de la inyección de AVP durante 10 días consecutivos. Se investigó la concentración de espermatozoides, la hormona testosterona y la histología testicular de todos los grupos. Las expresiones de proteínas reguladoras agudas (StAR) fosforiladas con tirosina y esteroidogénicas testiculares se examinaron mediante inmunotransferencia de tipo Western. Los resultados mostraron que CMC contiene TPC (39.24 ± 0.65 ug / mg de ácido de ajo), capacidades antioxidantes (FRAP = 33.08 ± 0.21 ug / mg de ácido ascórbico equivalente, IC50 de DPPH = 389.8 ± 3.20 ug / ml) y momordicina I (404.9 mg) / g CMC). La concentración de esperma en el grupo MCP80 + AVP aumentó en comparación con el grupo AVP. El nivel de testosterona en los grupos tratados con CMC aumentó significativamente. La CMC protegió el daño testicular y pudo prevenir la disminución de StAR y una expresión de proteína fosforilada de 50 kDa en los testículos tratados con AVP. En conclusión, la CMC tiene efectos antioxidantes y puede prevenir la toxicidad reproductiva en ratas machos inducidas por VPA.


Subject(s)
Animals , Male , Rats , Testis/drug effects , Plant Extracts/administration & dosage , Momordica charantia , Antioxidants/administration & dosage , Organ Size , Phenols/analysis , Spermatozoa/drug effects , Sterols/analysis , Testis/pathology , Testosterone/analysis , Plant Extracts/chemistry , Blotting, Western , Chromatography, High Pressure Liquid , Valproic Acid/toxicity , Rats, Wistar , Protective Agents , Anticonvulsants/toxicity
10.
Arch. endocrinol. metab. (Online) ; 62(3): 325-331, May-June 2018. tab, graf
Article in English | LILACS | ID: biblio-950072

ABSTRACT

ABSTRACT Objective: The testosterone:cortisol ratio (T:C) is suggested to be used in order to examine whether physical exercise generates either a "catabolic environment" or an "anabolic environment". The present study aims to evaluate the acute time-course profile of cortisol and testosterone due to an episode of physical exercise. A biphasic profile in the T:C ratio response was hypothesized. Materials and methods: Morning sessions of treadmill running at two different intensities (Heart Rate at 65% and 80% of the maximum cardiac reserve) were performed by 6 male non-runners (NR) and 12 trained male runners (subdivided into trained runners T1 and T2). Cortisol and testosterone were measured in saliva. NR and T1 ran for 30 minutes at both intensities, and T2 ran for 46 minutes (± 4.1) at 65% and 42 minutes (± 3.5) at 80%. Results: In the 80% heart rate target, both groups of runners showed the biphasic time-profile, while the non-runners group did not. However, at the 65% level, none of the groups presented the hypothesized biphasic response. Conclusions: A biphasic time-profile in the testosterone:cortisol ratio can be seen in short-bout, high intensity exercise (treadmill running) during the morning in men trained for this specific physical activity.


Subject(s)
Humans , Male , Running/physiology , Saliva/chemistry , Testosterone/analysis , Hydrocortisone/analysis , Athletes , Heart Rate/physiology , Time Factors
11.
Rev. argent. endocrinol. metab ; Rev. argent. endocrinol. metab;55(1): 43-56, mar. 2018. graf.
Article in Spanish | LILACS | ID: biblio-1248114

ABSTRACT

Esta revisión fue realizada con el fin de evaluar nuestros resultados de laboratorio así como aquellos de la literatura que constituyen, a nuestro entender, aportes significativos en el síndrome de ovarios poliquísticos (SOP). Nuestro especial énfasis será presentar las limitaciones de las metodologías empleadas por nuestro grupo, comparativamente a las reportadas por otros investigadores. La determinación de andrógenos, en particular de Testosterona (TT), es quizá la de mayor complejidad dado que los resultados con los diferentes inmunoensayos empleados en nuestro medio producen resultados muy variables por los diferentes métodos y aún entre laboratorios que usan la misma metodología. La técnica de referencia es la cromatografía líquida en tándem con espectrometría de masa (LC-MSMS), de difícil aplicación en laboratorios de análisis clínicos debido a su alto costo y la imposibilidad de resolver numerosas muestras. En estudios previos demostramos que de los métodos habitualmente usados para evaluar la TT circulante, solo en 2 inmunoensayos los resultados obtenidos fueron satisfactoriamente validados indirectamente según el criterio del Consenso de los Centros para el Control y Prevención de Enfermedades (CDC, USA) contra LC-MSMS, los cuales fueron comparables a dicha metodología con niveles superiores a 0,5 ng/ml. El SOP puede presentar factores de riesgo aumentados para la enfermedad cardiovascular y la diabetes II. Estos factores no están debidamente categorizados en función de los distintos fenotipos del SOP. Se evaluarán los principales analitos empleados con este objetivo y los nuevos que aporten elementos de mayor especificidad en este sentido


This review was performed in order to evaluate our laboratory results as well as those of the literature that constitute, in our opinion, significant contributions in these pathophysiologies. Our special emphasis will be on presenting the limitations of the methodologies used by our group, compared to those reported by other researchers. The determination of androgens, in particular Testosterone (TT), is perhaps the most complex since the results with the different immunoassays used in our environment produce very variable results by the different methods and even between laboratories that use the same methodology. The reference technique is LC-MSMS, difficult to apply in clinical analysis laboratories because of its high cost and the inability to solve numerous samples. In previous studies, we demonstrated that, in comparison to LC-MSMS with the usual methods for evaluating circulating TT, the results obtained in only 2 immunoassays were satisfactorily validated indirectly according to the criteria of CDC against LC-MSMS, which were comparable to that methodology with levels higher than 0.5 ng/ml. PCOS may have increased risk factors for cardiovascular disease and diabetes II. These factors are not properly categorized according to the different phenotypes of PCOS. The main analytes used for this purpose will be evaluated and new ones that contribute elements of greater specificity in this sense


Subject(s)
Humans , Female , Polycystic Ovary Syndrome/etiology , Polycystic Ovary Syndrome/physiopathology , Testosterone/analysis , Phenotype , Mass Spectrometry/methods , Immunoassay/methods , Chromatography, Liquid/methods
12.
Int. j. morphol ; 34(2): 514-521, June 2016. ilus
Article in English | LILACS | ID: lil-787031

ABSTRACT

This study aimed to determine the antioxidant capacity of the Leucaena leucocephala aqueous shoot tips plus young leaves (LL-spl) extracts among three different fractions (LL-spl 10, 20, and 40 min) and to examine its acute toxicity on male reproductive parameters. The amount of the total phenolics in LL-spl extract was determined using a Folin-Ciocalteu reagent method and its antioxidant capacity was analyzed using 1, 1-diphenyl l-2-picrylhydrazyl radical scavenging and ferric reducing antioxidant powder methods. The LL-spl extract fraction with highest antioxidant capacity was used in animal treating. Male rats were divided into three groups (n= 5); control and groups treated with LL-spl 400 and 600 mg/Kg body weight for consecutive 40 days. The results showed that the LL-spl 40 min fraction possessed the highest antioxidant capacity. In addition, the LL-spl 400 and 600 groups showed no differences in weights of body, testis and epididymis, serum testosterone levels, and expression of testicular steroidogenic acute regulatory (StAR) protein. Significantly, LL-spl extract reduced the weight of seminal vesicle, sperm concentration, and seminiferous diameters compared with control. Moreover, LL-spl extract had adverse effect on testicular histology in inducing of seminiferous atrophy and degeneration including dilated blood vessels in interstitial tissue. It was concluded that although LL-spl extract possessing antioxidant capacity, in short term consumptions, it could be toxic to some male reproductive organs especially damaging testicular tissues.


El objetivo fue determinar la capacidad antioxidante del extracto de brotes acuosos con hojas nuevas de Leucaena leucocephala (LL-spl) en tres fracciones diferentes (LL-SPL 10, 20 y 40 min), además de examinar su toxicidad aguda sobre los parámetros reproductivos masculinos. Se determinó la cantidad de los fenoles totales en el extracto de LL-spl utilizando un método reactivo de Folin-Ciocalteu. La capacidad antioxidante se analizó por medio de 1-difenil-2-picrilhidracilo y/o métodos de reducción férrica de la capacidad antioxidante. La fracción de extracto LL-spl con mayor capacidad antioxidante fue utilizada en el tratamiento de los animales. Ratas macho fueron divididas en tres grupos (n= 5): el control y los grupos tratados con LL-spl 400 y 600 mg/kg peso corporal por 40 días consecutivos. El resultado mostró que la fracción LL-spl 40 min poseía la mayor capacidad antioxidante. Además, los grupos 400 y 600 LL-spl no mostraron diferencias según el peso corporal, testículos y epidídimo, niveles de testosterona y la expresión de proteínas testiculares. El extracto de LL-spl redujo de manera significativa el peso de la vesícula seminal, la concentración de espermatozoides y los diámetros de los túbulos seminíferos en comparación con el control. Por otra parte, el extracto de LL-spl tuvo un efecto adverso sobre la histología testicular por la inducción de atrofia y degeneración de los túbulos seminíferos, incluyendo a vasos sanguíneos dilatados en el tejido intersticial. Si bien el extracto LL-spl posee una capacidad antioxidante, ésta podría ser tóxica en el consumo a corto plazo para algunos órganos reproductores masculinos y especialmente dañino para los tejidos testiculares.


Subject(s)
Animals , Male , Rats , Antioxidants/pharmacology , Fabaceae , Plant Extracts/pharmacology , Plant Leaves/chemistry , Testis/drug effects , Body Weight/drug effects , Genitalia, Male/drug effects , Phenols/analysis , Rats, Sprague-Dawley , Seminiferous Tubules , Testosterone/analysis , Toxicity Tests, Acute
13.
Med. interna (Caracas) ; 32(1): 47-55, 2016. tab
Article in Spanish | LILACS, LIVECS | ID: biblio-1009605

ABSTRACT

La osteoporosis origina fracturas que ejercen un impacto considerable en la morbilidad y mortalidad. Objetivo: Evaluar la baja masa ósea en hombres y su relación con el eje gonadal. Métodos: Se estudiaron sujetos masculinos que acudieron a la Unidad de Investigación UNILIME-UC Hospital Universitario "Dr. Ángel Larralde" entre Marzo 2010 y Marzo 2015; la muestra quedó constituida por 70 sujetos con criterios de inclusión (> 35 años, baja masa ósea (osteopenia-osteoporosis) por ultrasonido de calcáneo e hipogonadismo subclínico por Test de Morley,posteriormente se realiza densitometría ósea (DEXA) y perfil hormonal. Los resultados se analizaron con programa SPSS. 18 para Windows, utilizando técnicas de análisis descriptivos y para la significancia estadística, el coeficiente correlación de Pearson, chi cuadrado, t student. Resultados: La edad promedio fue de 57,81±12.97 años de edad, predominando el grupo 60-69 años. Se observó alta prevalencia de baja masa ósea en 70% de los pacientes, con osteopenia, especialmente el cuello de fémur (CF), y significancia estadística (p<0,05) con la edad. Con respecto al perfil hormonal, hubo disminución de la testosterona total en 22,9% de los pacientes, con correlación positiva estadísticamente significativa (p<0,05) con la densidad mineral ósea (DMO) de cadera total (CT) y CF; aumento de la hormona luteinizante (LH) en 34,3% y disminución del estradiol total (E) en 12,9%, con correlación negativa estadísticamente significativa (p<0.05) entre la LH y DMO de CF y del E con la DMO de CT, CF y columna lumbar (CL); aumento de GTHS (Globulina transportadora de las hormonas sexuales) en 34,3% con correlación negativa estadísticamente significativa (p<0.001) con DMO de CT, CF y CL. Conclusiones: En las variaciones de la DEXA en población masculina debemos considerar: edad > 60 años, niveles séricos de testosterona total con la finalidad de corroborar el hipogonadismo subclínico y niveles séricos de GTHS, considerando a éste como predictor de baja masa ósea en el hombre(AU)


Osteoporosis causes fractures that have a considerable impact in morbility and mortality. Objective: to evaluate low bone mass in men and the relation with the gonadal axis. Methods: We examined men who attended the Unity of Investigation UNILIME-UC university Hospital "Dr Angel Larralde", Valencia, Venezuela between March 2010 ­ March 2015; the sample was 70 subjects ; inclusion criteria were (> 35 years, low bone mass (osteopenia-osteoporosis) by ultrasound of calcáneum, Subclinic hipogonadism by Test of Morley and subsequently the realization of Bone Mineral Density (BMD) and Laboratory (hormonal profile). The results were analysed using descriptive analysis,Pearson, and chi square technique* Results: we studied 70 men age 57.81±12.97 years.High prevalence of low bone mass was found 70% (osteopenia), being the most affected of femur, neck (p <0.05. There was an evident decline in Testosterone (22.9%,) with a statistically significant positive correlation (p <0.05) with bone mineral density (BMD) of total hip (TH) and neck of the femur (NF); increase in luteinizing hormone (LH) 34.3% and decrease in the total Estradiol (E) 12.9%, with statistically significantnegative correlation (p <0.05) between LH and BMD NF and E with BMD of TH, NF and L1- L4; increase of 34.3% with SHBG (sexual Hormone Blinding Globulin) statistically significant negative correlation (p <0.001) with BMD of TH, NF and L1-L4. Conclusion: In variations of BMD in men we must consider: age> 60 years, serum total testosterone in order to corroborate the subclinical hypogonadism and serum levels of SHBG, and consider this as a predictor of low bone mass in men(AU)


Subject(s)
Humans , Male , Adult , Middle Aged , Aged , Osteoporosis/drug therapy , Testosterone/analysis , Bone Diseases, Metabolic/etiology , Fractures, Bone , Bone Diseases , Bone Density , Internal Medicine
14.
Arq. bras. cardiol ; Arq. bras. cardiol;105(3): 256-264, Sept. 2015. tab, ilus
Article in English | LILACS | ID: lil-761506

ABSTRACT

Background:Testosterone deficiency in patients with heart failure (HF) is associated with decreased exercise capacity and mortality; however, its impact on hospital readmission rate is uncertain. Furthermore, the relationship between testosterone deficiency and sympathetic activation is unknown.Objective:We investigated the role of testosterone level on hospital readmission and mortality rates as well as sympathetic nerve activity in patients with HF.Methods:Total testosterone (TT) and free testosterone (FT) were measured in 110 hospitalized male patients with a left ventricular ejection fraction < 45% and New York Heart Association classification IV. The patients were placed into low testosterone (LT; n = 66) and normal testosterone (NT; n = 44) groups. Hypogonadism was defined as TT < 300 ng/dL and FT < 131 pmol/L. Muscle sympathetic nerve activity (MSNA) was recorded by microneurography in a subpopulation of 27 patients.Results:Length of hospital stay was longer in the LT group compared to in the NT group (37 ± 4 vs. 25 ± 4 days; p = 0.008). Similarly, the cumulative hazard of readmission within 1 year was greater in the LT group compared to in the NT group (44% vs. 22%, p = 0.001). In the single-predictor analysis, TT (hazard ratio [HR], 2.77; 95% confidence interval [CI], 1.58–4.85; p = 0.02) predicted hospital readmission within 90 days. In addition, TT (HR, 4.65; 95% CI, 2.67–8.10; p = 0.009) and readmission within 90 days (HR, 3.27; 95% CI, 1.23–8.69; p = 0.02) predicted increased mortality. Neurohumoral activation, as estimated by MSNA, was significantly higher in the LT group compared to in the NT group (65 ± 3 vs. 51 ± 4 bursts/100 heart beats; p < 0.001).Conclusion:These results support the concept that LT is an independent risk factor for hospital readmission within 90 days and increased mortality in patients with HF. Furthermore, increased MSNA was observed in patients with LT.


Fundamento:A deficiência de testosterona na insuficiência cardíaca (IC) está associada à diminuição da capacidade de exercício e mortalidade, mas o seu impacto sobre as readmissões é incerto. Além disso, sua relação com a ativação simpática é desconhecida.Objetivo:O presente estudo investigou o papel dos níveis de testosterona nas reinternações hospitalares, na mortalidade e na atividade nervosa simpática em pacientes com IC.Métodos:A testosterona total (TT) e a testosterona livre (TL) foram medidas em 110 pacientes do sexo masculino hospitalizados, com fração de ejeção < 45% eclassificação funcional da New York Heart Association (NYHA) IV, qualificados em dois grupos: 66 com baixos níveis de testosterona (BT) e 44 com testosterona normal (TN). Hipogonadismo foi definido como TT < 300 ng/dL e TL < 131 pmol/L. A atividade nervosa simpática muscular (ANSM) foi gravada por microneurografia em uma subpopulação de 27 pacientes.Resultados:O tempo de permanência hospitalar foi maior em pacientes BT em comparação com pacientes TN (37 ± 4 vs. 25 ± 4 dias; p = 0,008). Da mesma forma, o risco cumulativo de readmissão no período de um ano foi maior em pacientes BT (44% vs. 22%, p = 0,001). Na análise de uma única variável preditora, a testosterona total (HR = 2,77, IC 95% 1,58-4,85, p = 0,02) previu readmissão hospitalar no prazo de 90 dias. Na análise de uma única variável preditora, testosterona total (HR = 4,65, IC 95% 2,67-8,10, p = 0,009) e readmissão dentro de 90 dias (HR = 3,27, IC 95% 1,23-8,69, p = 0,02) previram aumento de mortalidade. Ativação neuro-humoral, estimada pela ANSM, foi significativamente maior nos pacientes BT em comparação aos do grupo TN (65 ± 3 vs. 51 ± 4 disparos/100BC; p < 0,001).Conclusão:Estes resultados sustentam o conceito de que BT é um fator de risco independente para a readmissão hospitalar dentro de 90 dias e para aumento de mortalidade em pacientes com IC. Além disso, observou-se aumento da ANSM em pacientes com baixos níveis de testosterona.


Subject(s)
Humans , Male , Middle Aged , Heart Failure/mortality , Patient Readmission , Testosterone/deficiency , Epidemiologic Methods , Length of Stay , Reference Values , Stroke Volume/physiology , Sympathetic Nervous System/physiopathology , Time Factors , Testosterone/analysis , Ventricular Function, Left/physiology
15.
Article in English | IMSEAR | ID: sea-159272

ABSTRACT

Aims and Objectives : The study was done to assess the hormones namely Estradiol, Testosterone, and Dehydroepiandrosterone-sulphate (DHEAs) one day before operation and on ninth post-operative day following surgical menopause. Materials and Methods : This is a cross sectional observational study. The study was done amongst the thirty four women aged between 40-48 years with functioning uterus and at least one ovary, not using any exogenous hormone preparations affecting ovarian function for last three months and having at least one menstrual period in three previous months were included in this study. They had under gone hysterectomy with bilateral salpingooophorectomy due to non-ovarian pathology. Fasting venous blood samples were taken one day before operation and on ninth post-operative day of surgical menopause Serum concentration of estradiol, testosterone, and DHEAS were determined. Results : The circulating estradiol level decreased significantly (p = 0.043) from 161 pg/ml preoperatively to 108 pg/ml. on ninth post-operative day after surgical menopause. In spite of reduction in mean testosterone level from 0.11 ng/ml. to 0.09 ng/ml. following surgical menopause, which is statistically insignificant (p = 0.247).There was no significant difference between the serum DHEA-S level before and after surgical menopause. A significant positive correlation was observed between pre-operative circulatory levels of DHEA-S with that of estradiol while there was absence of any significant co-relations corelations between any of the other pairs of values. Conclusion : The circulating estradiol level decreased significantly on ninth day after surgical menopause and significant positive correlation between pre-operative circulatory levels of DHEA-S with that of estradiol, but there was no significant co-relation between post-operative circulating estradiol with that of DHEA-S. Testosterone did not show any significant relation with estradiol neither in pre-operative period nor in post-operative condition.


Subject(s)
Adult , Dehydroepiandrosterone Sulfate/analysis , Dehydroepiandrosterone Sulfate/blood , Estradiol/analysis , Estradiol/blood , Female , Humans , Menopause, Premature/etiology , Menopause, Premature/physiology , Ovariectomy , Testosterone/analysis , Testosterone/blood
16.
Arq. bras. med. vet. zootec ; Arq. bras. med. vet. zootec. (Online);67(1): 7-14, 2/2015. tab, fig
Article in Portuguese | LILACS | ID: lil-741092

ABSTRACT

Estudou-se o efeito do Hormônio do Crescimento bovino (bGH) sobre os parâmetros seminais e a concentração sérica de testosterona de touros da raça Nelore. Dezesseis touros foram distribuídos em um delineamento fatorial 2 x 2 (duas idades e dois níveis de r-bST), com quatro animais em cada tratamento. As aplicações de r-bST foram realizadas a cada 14 dias, totalizando nove aplicações por animal, em um período experimental de 120 dias. As coletas de sêmen foram realizadas a cada 15 dias e, para determinar as concentrações de testosterona, foram realizadas coletas de sangue a cada quatro horas, num total de 24 horas, e a cada 30 dias a partir da primeira aplicação de r-bST. O sêmen dos touros adultos tratados com r-bST apresentaram maior motilidade e vigor (P<0,05) em relação aos animais controles (79,70±11,56% vs 64,06±23,65%) e (3,80±0,88 vs 2,92±1,25), respectivamente; entretanto, as demais características seminais não foram influenciadas (P>0,05) pelo tratamento com r-bST. Os aspectos físicos do sêmen dos touros jovens não foram afetados (P>0,05) pelo tratamento com r-bST. Entretanto o tratamento com r-bST diminuiu os defeitos morfológicos menores (delgado, gigante normal, pequeno normal, globoso, cabeça isolada normal, abaxial, cauda dobrada e enrolada levemente e gota distal) em relação aos jovens não tratados (P<0,05). As concentrações séricas de testosterona foram influenciadas (P<0,05) pelo tratamento, aos 120 dias após a primeira aplicação do r-bST, e apresentaram tendência de três picos no período de 24 horas.


The aim of this trial was to study the effect of Growth Hormone (GH) on the seminal parameters and testosterone profile from Nellore bulls. Sixteen bulls were allocated in a 2 x 2 factorial arrangement (two ages and two r-bST levels), with four animals per treatment. The r-bST was injected every 14 days, with a total of nine injections per animal, during the 120 days of the experimental period. The semen collections were done every 15 days and blood samples were collected in four hour intervals for 24 hours, and in 30 day intervals from the first r-bST injection for testosterone profile. The semen of adult bulls treated with r-bST showed greater MOT and VIG (P<0.05) in relation to the control (79.70±11.56% vs 64.06±23.65%) and (3.80±0.88 vs 2.92±1.25) respectively; however, the other evaluated seminal parameters were not affected (P>0.05) by the r-bST treatment. The physical measurements of the semen of young animals was also unaffected (P>0.05) by r-bST injection. However, the treatment with r-bST decreased the number of minor morphologic defects (narrow head, giant head, small normal head, round head, free normal head, abaxial implantation, simple bent tail and distal droplet) compared to untreated young bulls (P<0.05). The serum testosterone concentration was influenced (P<0.05) by treatment, at 120 days after the first injection of r-bST and they showed a tendency of three picks in a 24 hour period of sampling.


Subject(s)
Animals , Male , Cattle , Testosterone/analysis , Semen Analysis/veterinary , Growth Hormone
18.
Arq. bras. med. vet. zootec ; Arq. bras. med. vet. zootec. (Online);66(5): 1392-1400, Sep-Oct/2014. tab, graf
Article in Portuguese | LILACS | ID: lil-729779

ABSTRACT

Objetivou-se estudar a morfometria corpórea, as características do sêmen, o perfil proteico do plasma seminal em SDS-PAGE e a concentração sérica de testosterona em cervos-sambar (Cervus unicolor), criados em cativeiro, na estação reprodutiva da primavera. Quatro machos com idades entre 12 e 36 meses foram avaliados em quatro momentos, com intervalos de sete dias, com peso corpóreo (60,5 a 89,0kg), índice de massa corporal (93,07kg/m2 a 126,56kg/m2), volume do ejaculado (0,50±0,35mL a 0,75±0,28mL), motilidade espermática (87,75±4,78% a 90,00±7,07%), defeitos totais (17,25±5,81% a 47,72±17,55%), testosterona sérica (6,43±4,33ng/dL a 166,00±64,48ng/dL) e proteínas do plasma seminal com bandas entre 7,6 e 142kDa. As características dos ejaculados não diferiram (P>0,05) entre as três primeiras colheitas. Houve diferença (P<0,05) para os defeitos espermáticos com elevação na quarta colheita. No plasma seminal de cada cervo, foram identificadas de 16 a 27 bandas de proteínas entre 7,6 e 142kDa. Conclui-se que a qualidade espermática foi satisfatória na primavera. O estresse das contenções sucessivas causou queda da qualidade espermática. A idade influi na concentração sérica de testosterona, a qual foi maior nos cervos aos 36 meses...


The aim of this work was to study the body morphometry, semen characteristics, seminal plasma protein profile in SDS-PAGE and serum testosterone concentration in Sambar Deer (Cervus unicolor), in captivity in the breeding season (spring). Four males aged between 12 and 36 months were assessed in four moments with intervals of seven days with body weight (60.5 to 89.0kg), body mass index (93.07 to 126.56kg/m2), ejaculate volume (0.50±0.35mL to 0.75±0.28mL), sperm motility (87.75±4.78% to 90.00±7.07% ), total defects (17.25±5.81% to 47.72±17.55%), serum testosterone (6.43±4.33 ng/dL to 166.00±64.48ng/dL) and seminal plasma proteins with bands between 7.6 and 142 kDa. The characteristics of ejaculates did not differ (P>0.05) among ejaculates (1st, 2nd and 3rd). There were differences (P<0.05) for sperm defects elevation on the fourth ejaculate. In seminal plasma 16 to 27 protein bands between 7.6 and 142 kDa were identified. In conclusion, sperm quality was satisfactory in the spring and the stress of successive contentions decreased sperm quality. Also, there is influence of age upon serum testosterone concentration which was higher in deer at 36 months...


Subject(s)
Animals , Semen Analysis/veterinary , Deer , Sperm Capacitation , Androgens/analysis , Electrophoresis, Polyacrylamide Gel/veterinary , Testosterone/analysis
19.
Int. j. morphol ; 32(3): 844-849, Sept. 2014. ilus
Article in English | LILACS | ID: lil-728277

ABSTRACT

Nicotine consumption can decrease fertility drive in males through inducing oxidative stress and DNA damage. The color of turmeric is because of a substance called curcumin for which some anti-oxidative and anti-inflammatory properties have been identified. In this study, various doses of curcumin (10, 30 and 60 mg/kg) and curcumin plus nicotine (10, 30 and 60 mg/kg) were administered intraperitoneally to male mice for 28 consequent days and reproductive parameters were determined. The results indicated that nicotine administration (0.5 mg/kg) significantly decreased testosterone level, count and motility of sperms, and testis weight compared to control group. However, increasing the dose of curcumin significantly increased reproductive indices in most of the groups. Thus, it seems that curcumin inhibits nicotine-induced adverse effects on reproductive parameters.


El consumo de nicotina puede disminuir la fertilidad en los hombres mediante la inducción de estrés oxidativo y daño del ADN. El color de la cúrcuma se debe a una sustancia llamada curcumina en la cual se han identificado algunas propiedades anti-oxidantes y anti-inflamatorias. En este estudio se administraron diferentes dosis de curcumina (10, 30 y 60 mg/kg) y de curcumina más nicotina (10, 30 y 60 mg/kg) por vía intraperitoneal a ratones machos durante 28 días consecutivos y se determinaron los parámetros reproductivos. La administración de nicotina (0,5 mg/kg) disminuyó significativamente el nivel de testosterona, el número y motilidad de los espermatozoides, y peso de los testículos en comparación con el grupo control. Sin embargo, el incremento de la dosis de curcumina aumentó significativamente los índices reproductivos en la mayoría de los grupos. Este estudio sugiere que la curcumina inhibe los efectos adversos inducidos por la nicotina sobre los parámetros reproductivos.


Subject(s)
Animals , Male , Mice , Reproduction/drug effects , Testis/drug effects , Curcumin/administration & dosage , Nicotine/toxicity , Antioxidants/administration & dosage , Organ Size/drug effects , Seminiferous Tubules/drug effects , Sperm Count , Sperm Motility/drug effects , Testosterone/analysis , Curcumin/pharmacology , Antioxidants/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL